mouse iga igg double color elispot kit  (Cellular Technology Ltd)

Journal: Human Vaccines & Immunotherapeutics

Article Title: Influenza hemagglutinin and neuraminidase multivalent vaccine elicits broader protective immune responses compared to vaccine formulations composed of hemagglutinin or neuraminidase

doi: 10.1080/21645515.2025.2599611

Figure Lengend Snippet: B cell response after vaccination in naïve or pre-immune mice. DBA/2J mice were vaccinated intranasally at four-week intervals with c-di-AMP as adjuvant. Pre-immune mice were previously infected with seasonal H1N1, H3N2, and IBV. Spleens were collected 7 d after final vaccination for ELISPOT assay to enumerate IgA/IgG antibody secreting cells against individual vaccine components. Statistical differences were analyzed using unpaired t-test with GraphPad Prism 9 software (GraphPad, San Diego, CA, USA). A p value of less than .05 was defined as statistically significant (*, p < .05).

Article Snippet: Spleens were harvested 7 d post final vaccination (n = 3) and ELISPOT assay was performed using Mouse IgA/IgG Double-Color ELISPOT kit (CTL, Shaker Heights, OH, USA) per manufacturer’s instructions.

Techniques: Adjuvant, Infection, Enzyme-linked Immunospot, Software

Journal: bioRxiv

Article Title: Defining a highly conserved B cell epitope in the receptor binding motif of SARS-CoV-2 spike glycoprotein

doi: 10.1101/2024.12.06.625234

Figure Lengend Snippet: (A) Nine participants immunized previously with three doses of ancestral WA1 vaccine were enrolled and followed after boosting. All participants’ blood was collected at baseline, week 1, 4, 8 and 17 following boosting. Fine needle aspirate of draining axillary lymph nodes were collected from all participants at week 8 post-boosting. ( B) Frequency of bivalent vaccine WA1 and BA.1 S + antibody responses were probed by ELISpot at week 1 corresponding to peak plasmablast response time-point. ( C) All participants’ (n = 9) plasma anti-S IgG titres were measured at week 0 and 4 against WA1 and BA.1 Spike protein. Results are from technical duplicates of one experiment. P values were determined by two-tailed Wilcoxon matched-pairs signed rank test. ( D) and (E) Representative flow cytometry plots and frequencies of S-binding germinal centre B cells ( BCL6 + CD38 int IgD lo CD19 + CD3 - ) and lymph node plasma cells (CD20 lo CD38 + IgD lo CD19 + CD3 - ) of fine needle aspirates from draining axillary lymph nodes at week 8 post boosting. Horizontal lines indicate median in frequency plots.

Article Snippet: Direct ex-vivo ELISpot assays were performed to determine the number of total, recombinant S-binding IgG- and IgA-secreting cells present in PBMC and enriched BMPC samples using IgG/IgA double-color ELISpot Kits (Cellular Technology Limited) according to the manufacturer’s instructions.

Techniques: Enzyme-linked Immunospot, Two Tailed Test, Flow Cytometry, Binding Assay

Journal: NPJ Vaccines

Article Title: Shigella virulence protein VirG is a broadly protective antigen and vaccine candidate

doi: 10.1038/s41541-023-00797-6

Figure Lengend Snippet: a , b Spleen and bone marrow were obtained from mice immunized IM with 20 µg of VirGα (IM) or IN with S. flexneri 2a (sl Sf2a-IN) that survived S. flexneri 2a lethal challenge. Single-cell suspensions from individual mice in each group were pooled, and VirGα-specific and total IgG and IgA ASC were measured by ELISpot in quadruplicates. Bars represent mean values per 10 6 cells ± SEM; * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001 by t test.

Article Snippet: The frequencies of total and VirGα-specific IgG- and IgA-secreting cells were determined using a mouse IgA/IgG double-color ELISpot assay kit [Catalogue # mIgGIgA-DCE-1M/2, ImmunoSpot® ELISpot Kit, Cellular Technology Limited (CTL), Cleveland, OH] according to the manufacturer’s instructions.

Techniques: Enzyme-linked Immunospot